| Popis: |
Neuromuscular blocking agents are used as adjuvants prior to general anesthesia ensuring optimal conditions for endotracheal intubation, mechanical ventilation and relaxation of abdominal muscular tone. Currently, the standard procedure for reversal of neuromuscular blocks (NMB) is I.V. administration of Neostigmine. Neostigmine is an acetylcholinesterase inhibitor that ensures reversal of NMB by increasing the level of acetylcholine in the neuromuscular junction. Compared to Neostigmine, Sugammadex more rapidly reverses non-depolarizing neuromuscular blocks (NMB) and it is known to cause fewer adverse event. Due to the lack of clinical data, Sugammadex is currently not recommend for pregnant patients undergoing non-obstetric surgery, even though, studies conducted on other patient groups indicate that Sugammadex might be a safer and more efficient choice of treatment compared to Neostigmine. Currently, there is little clinical data regarding the administration of Sugammadex to pregnant patients. Our review aim to present the most recent data on safety of sugammadex for reversal of NMB. Safety for mother and fetus/child in non-obstetric surgery. |
